Table 1.
Correlation between clinicopathological features and ACTA2/IL6 mRNA co-expression in bladder cancer patients
| Features | No. of patients | ACTA2/IL6 expression | p value | |
|---|---|---|---|---|
| Low/Low | High/High | |||
| Age (years) | ||||
| < 65 | 53 | 28 (52,8%) | 25 (47,2%) | 0.6950 |
| > 65 | 51 | 24 (47,1%) | 27 (52,9%) | |
| Gender | ||||
| Male | 85 | 48 (56,5%) | 37 (43,5%) | 0.0058** |
| Female | 19 | 4 (21,1%) | 15 (78,9%) | |
| Invasiveness | ||||
| Superficial | 67 | 43 (64,2%) | 24 (35,8%) | 0.0001**** |
| Invasive | 37 | 9 (24,3%) | 28 (75,7%) | |
| Grade | ||||
| Low | 75 | 43 (57,3%) | 32 (42,7%) | 0.0179* |
| High | 29 | 9 (31,0%) | 20 (69,0%) | |
| Lymph node metastasis | ||||
| N0 | 92 | 50 (54,3%) | 42 (45,7%) | 0.0281* |
| N1, N2 | 11 | 2 (18,2%) | 9 (81,8%) | |
| Metastatic invasion | ||||
| M0 | 99 | 50 (50,5%) | 49 (49,5%) | 1.000 |
| M1 | 5 | 2 (40,0%) | 3 (60,0%) | |
| Recurrence (non-invasive cancer only) | ||||
| No | 36 | 26 (72,2%) | 10 (27,8%) | 0.2016 |
| Yes | 31 | 17 (54,8%) | 14 (45,2%) | |
| Progression | ||||
| No | 63 | 34 (54,0%) | 29 (46,0%) | 0.3254 |
| Yes | 41 | 18 (43,9%) | 23 (56,1%) | |
Fisher’s exact test with 50% lower or higher level of mRNA expression